INOVIO PHARMACEUTICALS, INC. Revenue from Grants (Deprecated 2018-01-31)
INOVIO PHARMACEUTICALS, INC. (INO) reported Revenue from Grants (Deprecated 2018-01-31) of $92.59 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromGrants · last filed 2018-05-09
- INOVIO PHARMACEUTICALS, INC. revenue from grants (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $92.59K, a 98.23% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. revenue from grants (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $980.44K, a 87.33% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. revenue from grants (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.46M, a 84.53% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. revenue from grants (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $2.80M, a 26.65% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. revenue from grants (deprecated 2018-01-31) for fiscal 2017 was $10.47M, a 61.40% decline from fiscal 2016.
- INOVIO PHARMACEUTICALS, INC. revenue from grants (deprecated 2018-01-31) for fiscal 2016 was $27.14M, a 110.09% increase from fiscal 2015.
- INOVIO PHARMACEUTICALS, INC. revenue from grants (deprecated 2018-01-31) for fiscal 2015 was $12.92M, a 404.40% increase from fiscal 2014.
- INOVIO PHARMACEUTICALS, INC. revenue from grants (deprecated 2018-01-31) for fiscal 2014 was $2.56M, a 32.66% decline from fiscal 2013.
| Period end | Revenue from Grants (Deprecated 2018-01-31) 3 month | Revenue from Grants (Deprecated 2018-01-31) 6 month | Revenue from Grants (Deprecated 2018-01-31) 9 month | Revenue from Grants (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $92.59K 10-Q · filed 2018-05-09 | $1.07M derived: sum of 2 quarters · filed 2018-05-09 | $2.53M derived: sum of 3 quarters · filed 2018-05-09 | $5.33M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | $980.44K 10-K · filed 2018-03-14 | $2.44M derived: sum of 2 quarters · filed 2018-03-14 | $5.23M derived: sum of 3 quarters · filed 2018-03-14 | $10.47M 10-K · filed 2018-03-14 |
| 2017-09-30 | $1.46M 10-K · filed 2018-03-14 | $4.25M derived: sum of 2 quarters · filed 2018-03-14 | $9.49M 10-Q · filed 2017-11-08 | $17.23M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-06-30 | $2.80M 10-K · filed 2018-03-14 | $8.04M 10-Q · filed 2017-08-08 | $15.77M derived: sum of 3 quarters · filed 2018-05-09 | $25.18M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-03-31 | $5.24M 10-Q · filed 2018-05-09 | $12.98M derived: sum of 2 quarters · filed 2018-05-09 | $22.39M derived: sum of 3 quarters · filed 2018-05-09 | $26.20M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $7.74M 10-K · filed 2018-03-14 | $17.15M derived: sum of 2 quarters · filed 2018-03-14 | $20.96M derived: sum of 3 quarters · filed 2018-03-14 | $27.14M 10-K · filed 2018-03-14 |
| 2016-09-30 | $9.41M 10-K · filed 2018-03-14 | $13.22M derived: sum of 2 quarters · filed 2018-03-14 | $19.40M 10-Q · filed 2017-11-08 | $23.14M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $3.81M 10-K · filed 2018-03-14 | $9.99M 10-Q · filed 2017-08-08 | $13.73M derived: sum of 3 quarters · filed 2018-03-14 | $21.31M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $6.18M 10-K · filed 2018-03-14 | $9.92M derived: sum of 2 quarters · filed 2018-03-14 | $17.50M derived: sum of 3 quarters · filed 2018-03-14 | $18.28M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $3.74M 10-K · filed 2017-03-15 | $11.32M derived: sum of 2 quarters · filed 2017-03-15 | $12.11M derived: sum of 3 quarters · filed 2017-03-15 | $12.92M 10-K · filed 2018-03-14 |
| 2015-09-30 | $7.58M 10-K · filed 2017-03-15 | $8.37M derived: sum of 2 quarters · filed 2017-03-15 | $9.18M 10-Q · filed 2016-11-09 | $9.76M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $784.77K 10-K · filed 2017-03-15 | $1.59M 10-Q · filed 2016-08-08 | $2.18M derived: sum of 3 quarters · filed 2017-03-15 | $2.79M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $808.57K 10-K · filed 2017-03-15 | $1.40M derived: sum of 2 quarters · filed 2017-03-15 | $2.01M derived: sum of 3 quarters · filed 2017-03-15 | $2.56M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | $586.50K 10-K · filed 2016-03-14 | $1.20M derived: sum of 2 quarters · filed 2016-03-14 | $1.76M derived: sum of 3 quarters · filed 2016-03-14 | $2.56M 10-K · filed 2017-03-15 |
| 2014-09-30 | $612.90K 10-K · filed 2016-03-14 | $1.17M derived: sum of 2 quarters · filed 2016-03-14 | $1.97M 10-Q · filed 2015-11-09 | $2.79M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $556.38K 10-K · filed 2016-03-14 | $1.36M 10-Q · filed 2015-08-10 | $2.17M derived: sum of 3 quarters · filed 2016-03-14 | $3.16M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | $804.95K 10-K · filed 2016-03-14 | $1.62M derived: sum of 2 quarters · filed 2016-03-14 | $2.61M derived: sum of 3 quarters · filed 2016-03-14 | $3.27M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | $811.20K 10-K · filed 2015-03-16 | $1.80M derived: sum of 2 quarters · filed 2015-03-16 | $2.47M derived: sum of 3 quarters · filed 2015-03-16 | $3.80M 10-K · filed 2016-03-14 |
| 2013-09-30 | $991.84K 10-K · filed 2015-03-16 | $1.66M derived: sum of 2 quarters · filed 2015-03-16 | $2.99M 10-Q · filed 2014-11-10 | $3.97M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | $665.05K 10-K · filed 2015-03-16 | $2.00M 10-Q · filed 2014-08-11 | $2.98M derived: sum of 3 quarters · filed 2015-03-16 | $3.59M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | $1.33M 10-K · filed 2015-03-16 | $2.31M derived: sum of 2 quarters · filed 2015-03-16 | $2.92M derived: sum of 3 quarters · filed 2015-03-16 | $3.23M derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | $977.97K 10-K · filed 2014-03-17 | $1.59M derived: sum of 2 quarters · filed 2014-03-17 | $1.90M derived: sum of 3 quarters · filed 2014-03-17 | $3.46M 10-K · filed 2015-03-16 |
| 2012-09-30 | $609.72K 10-K · filed 2014-03-17 | $918.64K derived: sum of 2 quarters · filed 2014-03-17 | $2.48M 10-Q · filed 2013-11-12 | $3.98M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $308.93K 10-K · filed 2014-03-17 | $1.87M 10-Q · filed 2013-08-09 | $3.37M derived: sum of 3 quarters · filed 2014-03-17 | $5.83M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $1.56M 10-K · filed 2014-03-17 | $3.06M derived: sum of 2 quarters · filed 2014-03-17 | $5.52M derived: sum of 3 quarters · filed 2014-03-17 | $7.80M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | $1.50M 10-K · filed 2013-03-18 | $3.95M derived: sum of 2 quarters · filed 2013-03-18 | $6.24M derived: sum of 3 quarters · filed 2013-03-18 | $9.23M 10-K · filed 2014-03-17 |
| 2011-09-30 | $2.45M 10-K · filed 2013-03-18 | $4.74M derived: sum of 2 quarters · filed 2013-03-18 | $7.73M 10-Q · filed 2012-11-07 | $9.94M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | $2.29M 10-K · filed 2013-03-18 | $5.27M 10-Q · filed 2012-08-09 | $7.49M derived: sum of 3 quarters · filed 2013-03-18 | $8.56M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $2.99M 10-K · filed 2013-03-18 | $5.20M derived: sum of 2 quarters · filed 2013-03-18 | $6.27M derived: sum of 3 quarters · filed 2013-03-18 | $7.23M derived: sum of 4 quarters · filed 2013-03-18 |
| 2010-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $3.29M derived: sum of 2 quarters · filed 2013-03-18 | $4.25M derived: sum of 3 quarters · filed 2013-03-18 | $5.55M 10-K · filed 2013-03-18 |
| 2010-09-30 | $1.08M 10-Q · filed 2011-11-07 | $2.04M derived: sum of 2 quarters · filed 2011-11-07 | $3.34M 10-Q · filed 2011-11-07 | |
| 2010-06-30 | $960.17K 10-Q · filed 2011-08-05 | $2.26M 10-Q · filed 2011-08-05 | ||
| 2009-12-31 | $4.01M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |